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Sweat chloride concentrations are higher in I RT-positive newborns 
with one CFTR mutation than in other !RT-positive neonates 
G.F. Mergni, F. Festini, G. Taccetti, T. Repetto, F. Chiarelli 
Cf Center of Tuscany, Florence, Italy 
A neonatal screening program for CF has been carried out since 1991 by the CF 
Center of Florence on all the newborns of Tuscany, Italy, using a IRT/Lactase/IRT 
protocol. 
From Feb. 20, 2001 to May 20, 2003, all the blood spots of children who resulted 
!RT-positive were tested for CFfR mutations (32 mutations, PCR OLA assay and 
DGGE analysis). 
Aim: to investigate if difference exists in sweat chloride concentrations between 
non-CF neonates who were !RT-positive and carriers of a CFfR mutation, and those 
who were !RT-positive and negative to the genetic test. 
During the period, 64,114 newborns were screened for CF and 744 resulted IRT-
positive and were not affected by CF. Among them, 48 (6.4%) resulted carriers of a 
CFlR mutation (DF508 carriers n= 32, 66.6%). Of 744 non-CF, !RT-positive 
children, according to the screening protocol 161 nnderwent a sweat test (Gibson & 
Cook). 
The minimum quantity of sweat collected was 60 mg (sweat rate 1.05 g/m2/min); 
the mean age at sweat test was 65 days, SD 42. Of these 161 neonates, 26 (16.1 %) 
resulted to be carriers of a CFIR mutation (DF508 carriers n=18) and 135 were 
negative to genetic testing. 
The mean sweat chloride concentration ofCFIR mutation carriers was 16.4 mEq/L, 
SD 8.1(median14, range 8-41), whereas that of newborns negative to genetic test 
was 13.5 mEq/L, SD 5.1 (median 13, range 4-34) p=0.02, difference 2.9 mEq/L, 
CI95%: 0.5-5.2. 
In our population we fonnd a statistically significant difference between the mean 
sweat chloride concentration of non-CF, !RT-positive newborns with a CFlR 
mutation and that of those negative to genetic test. 
These findings might be interpreted as a possible result of the mutated CFlR 
protein action on the sweat chloride concentration in the carrier newborns. 
Telethon Italy, Grant EC1208/2000 
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Diagnosis CF?: Functional chloride secretion, complete CFTR 
screening, sequencing and transcript analysis in patients with 
inconclusive sweat test and CFTR mutation screening 
N. Derichs1, J. Sanz2, C. Rokahr1, T. von Kaenel2, U. Laabs1, B. Siebert1, B. 
Tilmmler1, S. Gallati 2, M. Ballmann1 
1Department of Pediatric Pulmo1Wlogy and CF Research Group, Medical School 
Han1Wver, Germany; 2Division of Human Genetics, Children's University-Hospital, 
Bern, Switzerkmd 
Exclusion of mild or monosymptomatic CF often is difficult in condition of 
inconclusive sweat test and CFTR mutation screening. Fnnctional analysis ofCFlR 
chloride secretion by both nasal potential difference (nPD) and intestinal current 
measurement (ICM) has been proven to be of high sensitivity and specificity. This 
study aimed to correlate these methods with an extended genetic analysis in a 
preselected patient cohort with borderline diagnostic features, and to establish a 
most informative procedure. 
From n=164 patients with mild CF phenotype, inconclusive sweat test and/or CFTR 
mutation screening, n=115 were investigated by ICM and n=49 by both nPD and 
ICM. Individuals with borderline/pathological sweat chloride or low 
normal/pathological chloride secretory responses (n=30) were included into 
extended genetic evaluation (complete CFTR mutation screening exon 1-27 /intron 
11+19 by SSCP-HD analysis, sequencing and transcript analysis). 
In n=7 patients the results of ICM and/or nPD were CF-typical. No correlation with 
absolute sweat chloride concentrations was seen. Electrophysiological result 
interpretation was confirmed by the extended genetic investigation, revealing two 
pathogenic CFTR mutations only in the patients classified as CF upon ICM/nPD. 
Chloride secretory phenotypes were consistent with the extended genetic analysis in 
this highly informative patient cohort. ICM/nPD evaluation of patients with 
borderline phenotype aids in the diagnostic process and should be applied in cases 
of inconclusive routine tests. 
477 
Congenital bilateral absence of the vas deferens (CBAVD): when does 
it lead to cystic fibrosis (CF) diagnosis? 
G. Pizzamiglio1, M.A. Monti1, L. Barbetta1, M. Seia2 
1CF Adult Center, Internal Medicine, ICP, Milan, Italy; 2Molecular Genetics Lah, 
ICP, Milan, Italy. 
Introduction: male infertility, particularly CBAVD is a typical finding in classical 
CF. Atypical CF may presents as isolated CBAVD in patients (pts) with two CF 
mutations and positive or border line sweat test. CFlR dysfnnction is often 
associated with the etiopathogenesis of CB A VD. Aim of this study is to investigate 
the relationship between CBAVD and CF diagnosis. Methods: 13 pts with CBAVD 
and one/two CFIR mutations or polymorphism were referred to our CF center. 
Results: mean age was 32.5 yrs, min-max 26-39; clinical history was not relevant in 
all but 5 pts (respiratory symptoms). 8/13 pts had been smokers in their life. Genetic 
assessment showed: a severe plus a mild mutation in 8/13 cases, a severe mutation 
plus poli-T 5n or 5/9 polymorphism in 4 pts and poli-T 5/9 alone in one pt. Sweat 
test (Cl mean value 69.9 mEq/l, min-max 46.2-101) was positive in 9 pts, border 
line in 4 pts. Mean FEVlwas 99.4%, min-max 84-116. Chest X-ray demonstrated 
bronchial markings in 9/13 pts, was normal in 4/13 pts. Sputum culture was positive 
for Pseudomonas aeruginosa in 4/13 pts, Stenotrophomonas maltophilia in 1 pt, 
Staphilococcus aureus in 1 pt, negative in 7 pts. Mean BMI was 24.3 min-max 20-
30. Sinusopathy was demonstrated in 8/13 pts, no other CF-related disease was 
detected at diagnosis. In conclusion a classical form of CF was confirmed in 4 pts, 
in 7 pts a diagnosis of atypical CF was performed and CF was temporarily excluded 
in 2 pts. No pt presented a relevant respiratory disease despite individual findings 
of infection, chest X-ray, anamnestic data. The prognosis of these pts is not 
foreseeable and they need to be monitored for the development of CF 
complications; treatment needs to be individualiz.ed. 
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p.S1235R: a cystic fibrosis causing or non-causing mutation? 
Results from a French Molecular collaborative study 
M. des Georges1, E. Girodon2, C. Guittard1, F. Chevalier3, C. Dorche3, T. Bienvenu4, 
V. Dumur5, M. Blayau6, A. Iron7, H. Mittre8, D. Feldmann9, M. Claustres 1 
1!.aboratoire de Ginetique Moleculaire, CHU, Montpellier, France, 2Mondor-
Creteil, 3Debrousse-Lyon, 4Cochin-Paris, 5Calmette-Lille, 6Pontchaillou-Rennes, 
1Pellegrin-Bordeaux, 8C!imenceau-Caen, 9Trousseau-Paris, France 
More than 1300 different mutations in the CFIR gene, causing or non-causing 
disease, have been reported to the CF Consortium. p.S1235R, initially reported in a 
CF patient with a second mutation on the same allele (p.G628R), has been fonnd at 
a frequency higher than that of many other mutations and its clinical significance is 
not clear. 
The aim of this study is to compare the phenotypes of57 subjects with p.S1235R in 
order to classify this sequence anomaly. They were referred for diagnosis of 
classical CF, non-classic or atypical phenotypes or carrier screening. The entire 
coding and flanking regions and six microsatellite markers were analyz.ed. 8 
patients (3 CF, 4 CBAVD, 1 ICP) and 2 normal individuals were compound 
heterozygotes for a severe CFIR mutation. p.S1235R was fonnd to be associated on 
the same allele with a stop mutation (p.R785X) in 2 CF patients with a severe 
disease and TG13-T5 in the 4 CBAVD patients. The CF patient with a mild 
phenotype, the ICP patient and the normal subjects did not carry a complex allele. 
Our data suggest that another CFfR mutation may influence the pathogenic effect 
ofp.Sl235R in severe classical CF or in patients showing pathology closely linked 
to mutations in the CFIR gene. However, p.S1235R alone, when combined in trans 
with a second CF mutation, may be associated with a mild phenotype or with 
absence of clinical manifestations. 
